The Rheumatology Research Foundation is the charitable arm of the ACR, advancing research and training to improve the health of people living with rheumatic disease. Thanks to the continued support of ACR and ARP members, the Foundation is the largest private funding source for rheumatology research and training programs in the U.S. In all, the…

Meet the Incoming Arthritis & Rheumatology Editor in Chief, Dr. Daniel Solomon
Daniel Solomon, MD, MPH, has practiced rheumatology for more than 20 years, all while conducting translational and clinical research and teaching young clinicians. Soon, he will also step into the role of editor in chief of Arthritis & Rheumatology, as Richard J. Bucala, MD, PhD, ends his tenure. He will assume some duties during a…
Potential Link Between OA & Gout
Monosodium urate (MSU) crystal formation, deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. These researchers examined the effects of human cartilage homogenates on MSU crystallization and MSU crystal-induced inflammation…

Year in Review: Rheumatic Disease Research in 2019
ATLANTA—Encouraging data on interleukin (IL) 23/IL-17 pathway drugs in psoriatic arthritis (PsA), JAK inhibitors in rheumatoid arthritis (RA) treatment and new evidence on physical activity and bone health in women were among the highlights of the 2019 ACR/ARP Annual Meeting’s Clinical Year in Review. Susan Manzi, MD, MPH, director of the Lupus Center for Excellence…

Management of Meniscal Tears: Surgery May Not Be Necessary
Patients with meniscal tear experience similar levels of reduced pain and improved physical function when treated with either arthroscopic partial meniscectomy or physical therapy, according to a recent study. The study also found these improvements were long term—lasting through the five-year follow up…

Leading Boldly: Transforming Rheumatology Campaign Makes Progress
In 2018, the Rheumatology Research Foundation embarked on its third and most ambitious fundraising campaign, Leading Boldly: Transforming Rheumatology, with a goal of raising $75 million over five years. The campaign supports Foundation programs to recruit the best and brightest into the field, train rheumatology professionals at all career stages and support investigators conducting research…

2019 EULAR/ACR SLE Classification Criteria Offer Improved Sensitivity & Specificity
The new EULAR/ACR classification criteria for SLE offer improved sensitivity and specificity, as well as more accurately reflect the current tests used to clinically diagnose SLE. A positive ANA test is obligatory…
Cryoglobulins: Quantified & Characterized
This study used up-to-date techniques to perform an exhaustive immunologic description of cryoglobulins with regard to characterization and quantification…

Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?
Patients with axial spondyloarthritis have a chronic, immune-mediated inflammatory disease that tends to localize to the sacroiliac joints and spine. Ankylosing spondylitis is, perhaps, the most representative of this group of diseases. Rheumatologists treat patients with axial spondyloarthritis with biologics, such as tumor necrosis factor inhibitors (TNFi’s), which can improve quality of life, activity and…

Research Sheds Light on Scleromyxedema, a Rare Skin Disorder
Scleromyxedema is a rare, mucinous skin disorder of unknown origin, one of a number of conditions that mimic systemic sclerosis. Although cases of scleromyxedema remain rare, a better understanding of its mechanisms of action could have implications for the research and treatment of scleroderma and related autoimmune conditions, says Laura K. Hummers, MD, ScM, co-director…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 123
- Next Page »